Cary Street Partners Investment Advisory LLC Grows Stake in Becton, Dickinson and Company (NYSE:BDX)

Cary Street Partners Investment Advisory LLC lifted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 12.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,032 shares of the medical instruments supplier’s stock after buying an additional 341 shares during the quarter. Cary Street Partners Investment Advisory LLC’s holdings in Becton, Dickinson and Company were worth $800,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the business. BlackRock Inc. lifted its stake in shares of Becton, Dickinson and Company by 5.7% during the 1st quarter. BlackRock Inc. now owns 23,794,080 shares of the medical instruments supplier’s stock valued at $5,889,987,000 after buying an additional 1,281,866 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich lifted its stake in Becton, Dickinson and Company by 98,105.4% in the 2nd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 6,929,375 shares of the medical instruments supplier’s stock worth $1,829,424,000 after purchasing an additional 6,922,319 shares in the last quarter. Geode Capital Management LLC lifted its stake in Becton, Dickinson and Company by 1.5% in the 1st quarter. Geode Capital Management LLC now owns 5,021,220 shares of the medical instruments supplier’s stock worth $1,239,745,000 after purchasing an additional 76,294 shares in the last quarter. Providence Capital Advisors LLC lifted its stake in Becton, Dickinson and Company by 25,185.5% in the 1st quarter. Providence Capital Advisors LLC now owns 4,492,216 shares of the medical instruments supplier’s stock worth $18,147,000 after purchasing an additional 4,474,450 shares in the last quarter. Finally, Moneta Group Investment Advisors LLC lifted its stake in Becton, Dickinson and Company by 95,813.8% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 4,045,643 shares of the medical instruments supplier’s stock worth $1,028,807,000 after purchasing an additional 4,041,425 shares in the last quarter. 86.72% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, Director Claire Fraser sold 848 shares of the firm’s stock in a transaction on Monday, August 28th. The shares were sold at an average price of $281.66, for a total value of $238,847.68. Following the sale, the director now owns 21,608 shares of the company’s stock, valued at approximately $6,086,109.28. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, EVP Richard Byrd sold 459 shares of the firm’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $274.48, for a total value of $125,986.32. Following the completion of the sale, the executive vice president now directly owns 3,444 shares of the company’s stock, valued at approximately $945,309.12. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Claire Fraser sold 848 shares of the firm’s stock in a transaction dated Monday, August 28th. The stock was sold at an average price of $281.66, for a total transaction of $238,847.68. Following the completion of the sale, the director now directly owns 21,608 shares of the company’s stock, valued at $6,086,109.28. The disclosure for this sale can be found here. Insiders own 0.31% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on BDX. Raymond James lowered their target price on shares of Becton, Dickinson and Company from $304.00 to $269.00 and set an “outperform” rating on the stock in a research note on Friday, November 10th. Piper Sandler lowered their target price on shares of Becton, Dickinson and Company from $305.00 to $280.00 and set an “overweight” rating on the stock in a research note on Friday, November 10th. Barclays increased their price target on shares of Becton, Dickinson and Company from $284.00 to $303.00 and gave the stock an “overweight” rating in a report on Monday, August 7th. StockNews.com initiated coverage on shares of Becton, Dickinson and Company in a report on Thursday, October 5th. They issued a “hold” rating on the stock. Finally, Citigroup decreased their price target on shares of Becton, Dickinson and Company from $282.00 to $260.00 in a report on Monday, October 2nd. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, Becton, Dickinson and Company presently has a consensus rating of “Moderate Buy” and an average target price of $282.38.

Becton, Dickinson and Company Price Performance

BDX stock opened at $233.27 on Monday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.81 and a current ratio of 1.31. Becton, Dickinson and Company has a 52 week low of $219.79 and a 52 week high of $287.32. The firm’s fifty day moving average is $256.46 and its 200 day moving average is $260.56. The firm has a market cap of $67.67 billion, a P/E ratio of 47.03, a P/E/G ratio of 1.88 and a beta of 0.55.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, November 9th. The medical instruments supplier reported $3.42 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $3.42. The business had revenue of $5.09 billion for the quarter, compared to analyst estimates of $5.02 billion. Becton, Dickinson and Company had a net margin of 7.66% and a return on equity of 13.91%. The company’s revenue was up 6.8% on a year-over-year basis. During the same quarter last year, the firm earned $2.75 EPS. Research analysts predict that Becton, Dickinson and Company will post 12.84 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, December 29th. Shareholders of record on Friday, December 8th will be issued a $0.95 dividend. This represents a $3.80 dividend on an annualized basis and a yield of 1.63%. The ex-dividend date is Thursday, December 7th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.91. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 73.39%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.